176 related articles for article (PubMed ID: 38362963)
1. Immunotherapy targeting PD‑1/PD‑L1: A potential approach for the treatment of cancer bone metastases (Review).
Hiraga T
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38362963
[TBL] [Abstract][Full Text] [Related]
2. A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review).
Kong X; Lu P; Liu C; Guo Y; Yang Y; Peng Y; Wang F; Bo Z; Dou X; Shi H; Meng J
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760188
[TBL] [Abstract][Full Text] [Related]
3. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
Giroux Leprieur E; Dumenil C; Julie C; Giraud V; Dumoulin J; Labrune S; Chinet T
Eur J Cancer; 2017 Jun; 78():16-23. PubMed ID: 28407528
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic modifications: Critical participants of the PD‑L1 regulatory mechanism in solid tumors (Review).
Ma X; Wu J; Wang B; Liu C; Liu L; Sun C
Int J Oncol; 2022 Nov; 61(5):. PubMed ID: 36129152
[TBL] [Abstract][Full Text] [Related]
6. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.
Moon EK; Langer CJ; Albelda SM
Ann Am Thorac Soc; 2017 Aug; 14(8):1248-1260. PubMed ID: 28613923
[TBL] [Abstract][Full Text] [Related]
7. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
8. [Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].
Guilleminault L; Carmier D; Heuzé-Vourc'h N; Diot P; Pichon E
Rev Pneumol Clin; 2015 Feb; 71(1):44-56. PubMed ID: 25687821
[TBL] [Abstract][Full Text] [Related]
9. Bispecific Aptamer-Based Recognition-then-Conjugation Strategy for PD1/PDL1 Axis Blockade and Enhanced Immunotherapy.
Sun Y; Mo L; Hu X; Yu D; Xie S; Li J; Zhao Z; Fang X; Ye M; Qiu L; Tan W; Yang Y
ACS Nano; 2022 Dec; 16(12):21129-21138. PubMed ID: 36484532
[TBL] [Abstract][Full Text] [Related]
10. Macrocyclic Compounds from Ansamycin Antibiotic Class as Inhibitors of PD1-PDL1 Protein-Protein Interaction.
Patil SP; Yoon SC; Aradhya AG; Hofer J; Fink MA; Enley ES; Fisher JE; Herb MC; Klingos A; Proulx JT; Fedorky MT
Chem Pharm Bull (Tokyo); 2018; 66(8):773-778. PubMed ID: 30068796
[TBL] [Abstract][Full Text] [Related]
11. Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
Bednova O; Leyton JV
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019653
[TBL] [Abstract][Full Text] [Related]
12. PD‑1/PD‑L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review).
Tang Q; Zhao S; Zhou N; He J; Zu L; Liu T; Song Z; Chen J; Peng L; Xu S
Int J Oncol; 2023 Apr; 62(4):. PubMed ID: 36866750
[TBL] [Abstract][Full Text] [Related]
13. Progress of immune checkpoint therapy in the clinic (Review).
Fan Y; Zhang C; Jin S; Gao Z; Cao J; Wang A; Li D; Wang Q; Sun X; Bai D
Oncol Rep; 2019 Jan; 41(1):3-14. PubMed ID: 30365127
[TBL] [Abstract][Full Text] [Related]
14. Predictors for clinical benefit of immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis.
El-Osta H; Jafri S
Immunotherapy; 2019 Feb; 11(3):189-199. PubMed ID: 30730276
[TBL] [Abstract][Full Text] [Related]
15. Treatment of patients with cancer using PD‑1/PD‑L1 antibodies: Adverse effects and management strategies (Review).
Sun G; Liu H; Shi X; Tan P; Tang W; Chen X; Sun G; Yang W; Kong X; Zheng Z; Cao H; Shao G
Int J Oncol; 2022 Jun; 60(6):. PubMed ID: 35485291
[TBL] [Abstract][Full Text] [Related]
16. Phospho‑STAT1 expression as a potential biomarker for anti‑PD‑1/anti‑PD‑L1 immunotherapy for breast cancer.
Nakayama Y; Mimura K; Tamaki T; Shiraishi K; Kua LF; Koh V; Ohmori M; Kimura A; Inoue S; Okayama H; Suzuki Y; Nakazawa T; Ichikawa D; Kono K
Int J Oncol; 2019 Jun; 54(6):2030-2038. PubMed ID: 31081058
[TBL] [Abstract][Full Text] [Related]
17. Nanobody against PDL1.
Li S; Jiang K; Wang T; Zhang W; Shi M; Chen B; Hua Z
Biotechnol Lett; 2020 May; 42(5):727-736. PubMed ID: 32006351
[TBL] [Abstract][Full Text] [Related]
18. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases.
Wang C; Sandhu J; Ouyang C; Ye J; Lee PP; Fakih M
JAMA Netw Open; 2021 Aug; 4(8):e2118416. PubMed ID: 34369992
[TBL] [Abstract][Full Text] [Related]
19. Anti‑PD‑1/PD‑L1 and anti‑CTLA‑4 associated checkpoint inhibitor pneumonitis in non‑small cell lung cancer: Occurrence, pathogenesis and risk factors (Review).
Hu X; Ren J; Xue Q; Luan R; Ding D; Tan J; Su X; Yang J
Int J Oncol; 2023 Nov; 63(5):. PubMed ID: 37681488
[TBL] [Abstract][Full Text] [Related]
20. Anti-PD1/PDL1 induced psoriasis.
Voudouri D; Nikolaou V; Laschos K; Charpidou A; Soupos N; Triantafyllopoulou I; Panoutsopoulou I; Aravantinos G; Syrigos K; Stratigos A
Curr Probl Cancer; 2017; 41(6):407-412. PubMed ID: 29096940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]